Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 20 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasRecruitingNCT02523014Phase 2
• A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous CarcinomaRecruitingNCT02491099Phase 2
• Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...RecruitingNCT02390752Phase 1
• Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingNCT02029001Phase 2
• Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or NilotinibRecruitingNCT01746836Phase 2
• Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityRecruitingNCT01639508Phase 2
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• A TQT Study of Effect of M2951 on Cardiac RepolarizationCompletedNCT07214935Phase 1Results posted
• Relative Bioavailability of Evobrutinib Tablet BatchesCompletedNCT07214922Phase 1Results posted
• Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and NintedanibCompletedNCT06717100Phase 1Results posted
• A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerTerminatedNCT06630325Phase 2Results posted
• A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the BloodCompletedNCT06504862Phase 1Results posted
• A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the BodyCompletedNCT06494761Phase 1Results posted
• A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female ParticipantsCompletedNCT06476834Phase 4Results posted
• Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TENCompletedNCT06474078Not applicableResults posted
• A Study to Investigate 14C-bemcentinib in Healthy Male SubjectsCompletedNCT06469138Phase 1Results posted
• Deucravacitinib (BMS-986165) for Pityriasis Rubra PilarisCompletedNCT06444399Phase 2Results posted
• Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)Active, not recruitingNCT06390852Phase 2Results posted
• Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)Active, not recruitingNCT06390826Phase 2Results posted
• Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)Active, not recruitingNCT06385483Phase 2Results posted
• Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)Active, not recruitingNCT06360575Phase 2Results posted
• Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)Active, not recruitingNCT06357975Phase 2Results posted
• Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)Active, not recruitingNCT06351371Phase 2Results posted
• Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)Active, not recruitingNCT06308822Phase 2Results posted
• Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)Active, not recruitingNCT06303167Phase 2Results posted
• A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy ParticipantsCompletedNCT06258174Phase 1Results posted
• A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic DermatitisCompletedNCT06238817Phase 3Results posted
• A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy ParticipantsCompletedNCT06215521Phase 1Results posted
• A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy ParticipantsCompletedNCT06215430Phase 1Results posted
• Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot StudyCompletedNCT06202560Not applicableResults posted
• A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy ParticipantsCompletedNCT06194214Phase 1Results posted
• Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy ParticipantsCompletedNCT06190691Phase 1Results posted
• Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy ParticipantsCompletedNCT06190678Phase 1Results posted
• A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult ParticipantsCompletedNCT06181006Phase 1Results posted
• A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy ParticipantsCompletedNCT06180980Phase 1Results posted
• A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy ParticipantsCompletedNCT06180967Phase 1Results posted
• A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male ParticipantsCompletedNCT06180954Phase 1Results posted
• A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy AdultsCompletedNCT06172348Phase 1Results posted
• A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy ParticipantsCompletedNCT06165146Phase 1Results posted
• A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy AdultsCompletedNCT06132867Phase 1Results posted
• A Study of Deucravacitinib to Treat LPP and FFACompletedNCT06091956Phase 2Results posted
• A Study in Healthy Men to Test How Zongertinib is Taken up in the Body When Taken With or Without FoodCompletedNCT06075277Phase 1Results posted
• A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the BloodCompletedNCT06070610Phase 1Results posted
• A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital PsoriasisTerminatedNCT06042920Phase 4Results posted
• A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Zongertinib in the BloodCompletedNCT06028464Phase 1Results posted
• JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow FailureActive, not recruitingNCT05998408Phase 1/2Results posted
• JAK/STAT Inhibition in CNS Kohlmeier-Degos DiseaseCompletedNCT05998395Phase 1/2Results posted
• Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).TerminatedNCT05997277Phase 2Results posted
• Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous UrticariaCompletedNCT05936567Phase 2Results posted
• A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy ParticipantsCompletedNCT05906836Phase 1Results posted
• Topical Ruxolitinib Evaluation in Chronic Hand EczemaCompletedNCT05906628Phase 2Results posted
• A Study in Healthy Men to Test How Zongertinib (BI 1810631) is Taken up and Processed by the BodyCompletedNCT05879991Phase 1Results posted
• A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult ParticipantsCompletedNCT05852340Phase 1Results posted
• A Study in Healthy Men to Test How Itraconazole Influences the Amount of Zongertinib (BI 1810631) in the BloodCompletedNCT05833139Phase 1Results posted
• Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)Active, not recruitingNCT05804045Phase 3Results posted
• Myositis Interstitial Lung Disease Nintedanib TrialCompletedNCT05799755Phase 4Results posted
• A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.CompletedNCT05795153Phase 3Results posted
• Ruxolitinib in Seborrheic DermatitisCompletedNCT05787860Phase 2Results posted
• A Study of TAS3351 in NSCLC Patients With EGFRmtTerminatedNCT05765734Phase 1Results posted
• A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)CompletedNCT05764161Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)CompletedNCT05755438Phase 3Results posted
• A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital VitiligoCompletedNCT05750823Phase 2Results posted
• A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe PsoriasisCompletedNCT05730725Phase 2Results posted
• Deucravacitinib for the Treatment of Palmoplantar PustulosisTerminatedNCT05710185Phase 4Results posted
• A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community SettingCompletedNCT05701995Phase 4Results posted
• The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.TerminatedNCT05696392Phase 4Results posted
• A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)CompletedNCT05673460Phase 1Results posted
• Janus Kinase Inhibition in Granuloma AnnulareCompletedNCT05650736Phase 2Results posted
• A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of AgeCompletedNCT05650333Phase 1Results posted
• Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis SuppurativaCompletedNCT05635838Phase 2Results posted
• A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male ParticipantsCompletedNCT05630287Phase 1Results posted
• A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy ParticipantsCompletedNCT05630274Phase 1Results posted
• A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT05601882Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque PsoriasisCompletedNCT05600036Phase 2Results posted
• International Sites: Novel Experimental COVID-19 Therapies Affecting Host ResponseTerminatedNCT05593770Phase 2/3Results posted
• A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen SclerosusCompletedNCT05593445Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen PlanusCompletedNCT05593432Phase 2Results posted
• Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell LymphomasActive, not recruitingNCT05583149Phase 2Results posted
• Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.TerminatedNCT05579769Phase 2Results posted
• Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid TumorsTerminatedNCT05571969Phase 1Results posted
• A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell LymphomaCompletedNCT05564052Phase 2Results posted
• Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast CancerActive, not recruitingNCT05558722Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia AreataTerminatedNCT05556265Phase 2Results posted
• Ritlecitinib for Cicatricial AlopeciaCompletedNCT05549934Phase 2Results posted
• Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.CompletedNCT05542342Phase 2Results posted
• A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China ExtensionCompletedNCT05523323Phase 3Results posted
• A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT05507580Phase 4Results posted
• Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated CytopeniasTerminatedNCT05502783Phase 2Results posted
• A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in RemissionTerminatedNCT05479058Phase 3Results posted
• Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp PsoriasisCompletedNCT05478499Phase 4Results posted
• A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 GeneTerminatedNCT05469178Phase 1/2Results posted
• A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal FunctionCompletedNCT05469100Phase 1Results posted
• A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy ParticipantsCompletedNCT05468164Phase 1Results posted
• Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Phase 2Results posted
• Study of Ruxolitinib Cream in Adolescents With Atopic DermatitisCompletedNCT05456529Phase 3Results posted
• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Active, not recruitingNCT05456191Phase 3Results posted
• A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy ParticipantsCompletedNCT05436912Phase 1Results posted
• Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to PeanutsCompletedNCT05432388Phase 2Results posted
• A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's DiseaseCompletedNCT05424276Phase 2Results posted
• Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's DiseaseCompletedNCT05422885Phase 1/2Results posted

← Tyrosine Kinase Inhibitors overview